ClinicalTrials.gg
TerminatedNCT03382977Updated May 8, 2026

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

A Phase 1/2 interventional study of VBI-1901 and Carmustine in Glioblastoma Multiforme, sponsored by VBI Vaccines Inc.. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by VBI Vaccines Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
VBI Bankruptcy

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
249th of 1,155
70 · median 33
Started
2017
with 54 others
Phase 1/2
190 of 1,302
32 open now
Registered
824th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 249th largest by enrollment of the 1,155 interventional ones that give a count, is one of 55 that started in 2017, is one of 190 in phase 1/2, and was the 824th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).

Read the detailed description

This is a three-part, dose-escalation study to define the safety, tolerability, and optimal dose level of candidate GBM vaccine VBI-1901 with subsequent extension of optimal dose level in recurrent GBM subjects and comparison with standard of care (SOC) treatment. Subjects in groups receiving VBI-1901 vaccination will continue to receive vaccine every 4 weeks until tumor progression per immunotherapy Response Assessment for Neuro-Oncology (iRANO)/Response Assessment for Neuro-Oncology (RANO) criteria.

03

Conditions studied

  • Glioblastoma Multiforme

Keywords

  • GBM
  • Glioblastoma
  • eVLP
  • VBI-1901
  • vaccine
  • immunotherapy
  • CMV
  • CNS
  • Brain
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

PART A DOSE ESCALATION

Inclusion Criteria: Part A Dose Escalation

  1. 18-70 years of age
  2. confirmed WHO grade IV glioblastoma
  3. Unequivocal evidence of a tumor recurrence (any number of recurrences) or progression after an initial treatment regimen (prior to enrollment on this study) as assessed by MRI of the brain with and without contrast within 30 days prior to the initiation of injections of VBI-1901. An initial therapy requires surgery and radiation therapy, with or without temozolomide. In addition, alternate therapy (with or instead of temozolomide) is permitted as part of initial therapy.
  4. Recovery from the effects of surgery.
  5. (dexamethasone or equivalent) dosage ≤ 4mg daily that has been stable or decreasing for at least 5 days.
  6. Recovery from prior therapy toxicity defined as resolution of all treatment-related adverse events (AEs) to Grade ≤ 1 or pre-treatment baseline (except alopecia).
  7. performance status (KPS) score ≥ 70%.
  8. Adequate organ function, including the following:

    1. (ANC) ≥ 1,000/μL, ≥ 100,000/μL
    2. Serum creatinine \< 1.5 × the (ULN)
    3. \< 1.5 × ULN
    4. (ALT) and aspartate aminotransferase (AST) \< 2.5 × ULN
  9. Women of : negative urine pregnancy test within 14 days prior to the start of VBI-1901 treatment.
  10. Female subjects of childbearing potential and sexually active male subjects must agree to use an acceptable form of for heterosexual activity (i.e., oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for >30 days before Screening, during the study, and for 60 days after the last dose of study drug).
  11. Female subjects without childbearing potential (spontaneous amenorrhea for > 12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction.
  12. Able and willing to comply with protocol requirements in the opinion of the Investigator, including being able to have an MRI.
  13. Written consent has been obtained.
  14. Tumor specimen available for central pathological review.

Exclusion Criteria: Part A Dose Escalation

  1. Contrast-enhancing residual tumor that is associated with either diffuse sub-ependymal or dissemination.
  2. Requirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of VBI-1901 treatment.
  3. Evidence of HCMV viremia in serum of > 18,200 (4.3Log10) IU/mL using FDA approved COBAS® AmpliPrep/COBAS® TaqMan® HCMV test (Roche).
  4. Surgical resection or major surgical procedure within 4 days prior to the start of VBI-1901, or stereotactic within 7 days prior to the start of VBI-1901.
  5. Active infection requiring intravenous antibiotics or antiviral.
  6. History of cancer (other than GBM or prostate) within the past 2 years that could negatively impact survival and/or potentially confound tumor response assessments within this study.
  7. Known disease or active systemic disease such as systemic lupus erythematosus, infection, virus or virus infections. Subjects with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  8. Immunosuppressive agent within 4 weeks prior to the start of VBI-1901 treatment.
  9. Evidence of intra-tumoral or peri-tumoral hemorrhage on baseline, other than those that are ≤Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans.
  10. Any condition which in the investigator's opinion makes the subject unsuitable for study participation.
  11. Lack of family or social support structure that would preclude continued participation in the study.

PART B OPTIMAL DOSE

Inclusion Criteria: Part B Optimal Dose

  1. 18-70 years of age.
  2. Histologically confirmed WHO grade IV glioblastoma.
  3. Unequivocal evidence of a first tumor recurrence with , of an area no greater than 400 mm2, which may include patients with resected first recurrence tumor after an initial treatment regimen (prior to enrollment on this study) consisting of surgical intervention (tumor resection) and radiation, with or without temozolomide chemotherapy (depending on the MGMT methylation status), as assessed by MRI of the brain with and without contrast within 30 days prior to the initiation of injections of VBI-1901. In addition, alternate chemotherapy (with or instead of temozolomide) is permitted as part of initial therapy.
  4. At least 12 weeks since radiotherapy treatment and/or 23 days after chemotherapy prior to first dose of VBI-1901.
  5. Recovery from the effects of surgery.
  6. Corticosteroid (dexamethasone or equivalent) dosage ≤ 4mg daily that has been stable or decreasing for at least 5 days.
  7. Recovery from prior therapy toxicity, defined as resolution of all treatment-related adverse events (AEs) to Grade ≤ 1 or pre-treatment baseline (except alopecia).
  8. Karnofsky performance status (KPS) score ≥ 70%.
  9. Adequate organ function, including the following:

    1. Absolute neutrophil count (ANC) ≥ 1,000/μL, platelets ≥ 100,000/μL; absolute lymphocyte count ≥ 500/uL;
    2. Serum creatinine \< 1.5 × the upper limit of normal (ULN);
    3. Bilirubin \< 1.5 × ULN;
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 × ULN.
  10. Women of childbearing potential must have a negative urine pregnancy test within 14 days prior to the start of VBI-1901 treatment.
  11. Female subjects of childbearing potential and sexually active male subjects must agree to use an acceptable form of contraception for heterosexual activity (i.e., oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for > 30 days before Screening, during the study, and for 60 days after the last dose of study drug).
  12. Female subjects without childbearing potential (spontaneous amenorrhea for > 12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction.
  13. Able and willing to comply with protocol requirements, in the opinion of the Investigator.
  14. Written consent has been obtained.
  15. Tumor specimen available for central pathological review.

Exclusion Criteria: Part B Optimal Dose

  1. Contrast-enhancing residual tumor that is any of the following:

    1. An area greater than 400mm2;
    2. Multi-focal (defined as two separate areas of contrast enhancement measuring at least 1 cm in 2 planes that are not contiguous on either fluid-attenuated inversion recovery (FLAIR) or T2 sequences);
    3. Associated with either diffuse sub-ependymal or leptomeningeal dissemination.
  2. IDH1/2 has been proven to be mutated by IHC or PCR or if recurrent GBM was previously a lower grade glioma and wildtype IDH1/2 status has not been confirmed.
  3. Requirement of systemic corticosteroid therapy > 4 mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of VBI-1901 treatment.
  4. Evidence of HCMV viremia in plasma of >18,200 (4.3log10) IU/mL using FDA approved COBAS® AmpliPrep/COBAS® TaqMan® HCMV test (Roche).
  5. Prior treatment involving immunotherapy, including oncolytic viruses, therapeutic vaccination, or biologics (e.g. monoclonal antibodies, such as bevacizumab) presumed to have immunomodulatory effects.
  6. Surgical resection or major surgical procedure within 14 days prior to the start of VBI-1901, or stereotactic biopsy within 14 days prior to the start of VBI-1901.
  7. Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following first recurrence/progressive disease. Excluded local therapies include stereotactic radiation boost, implantation of carmustine biodegradable wafers (Gliadel), intratumoral or convection- enhanced delivery administered agents, etc.
  8. Concurrent therapy with Optune® or use within 1 week of start of treatment with VBI-1901.
  9. Active infection requiring intravenous antibiotics or antivirals.
  10. History of cancer (other than GBM or prostate) within the past 2 years that has or local recurrence potential and could negatively impact survival and/or potentially confound tumor response assessments within this study.
  11. Known immunosuppressive disease or active systemic autoimmune disease such as systemic lupus erythematosus, human immunodeficiency virus infection, Hepatitis B virus or Hepatitis C virus infections. Subjects with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  12. Immunosuppressive agent within 4 weeks prior to the start of VBI-1901 treatment.
  13. Any severe adverse event or allergy suspected or attributed to the shingles vaccines that contains AS01B components.
  14. Evidence of intra- or peri-tumoral hemorrhage on baseline MRI scan, other than those that are ≤Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans.
  15. Any condition which in the investigator's opinion makes the subject unsuitable for study participation.
  16. Lack of family or social support structure that would preclude continued participation in the study.

PART C RANDOMIZED OPEN-LABEL STUDY EXTENSION

Inclusion criteria

INCLUSION CRITERIA

  1. 18 years of age or older (no age upper limit).
  2. Histologically confirmed supratentorial 2016 WHO classification grade IV Glioblastoma, IDH-wildtype or grade 4 in the 2021 WHO classification. Tumors that are histologically lower grade but are classified as glioblastoma using the WHO 2021 criteria because of molecular alterations (TERT promoter mutation and/or EGFR amplification and/or combined chromosome 7 gain/10 loss) are not eligible.
  3. Unequivocal evidence of a first tumor recurrence with measurable disease of an area no greater than 600 mm2, which may include patients with resected first recurrence tumor, after an initial treatment regimen (prior to enrollment on this study) consisting of surgical intervention (tumor resection) and radiation, with or without temozolomide chemotherapy (depending on the MGMT methylation status), as assessed by MRI of the brain with and without contrast completed within 30 days prior to screening visit, if not it should be performed as part of screening visit. In addition, alternate bio/chemotherapy (with or instead of temozolomide) other than nitrosourea is permitted as part of initial therapy.
  4. At least 12 weeks since radiotherapy treatment and/or 23 days after chemotherapy prior to first dose of VBI-1901 or SOC treatment. Patients with recurrent GBM within 12 weeks of radiation therapy may be included if they have surgically proven tumor recurrence (i.e.

    this is proven to not be pseudoprogression).

  5. Recovery from the effects of surgery.
  6. Corticosteroid (dexamethasone or equivalent) dosage ≤ 2 mg daily that has been stable for at least 5 days before randomization into the study.
  7. Recovery from prior therapy toxicity, defined as resolution of all treatment related adverse events (AEs) to Grade ≤ 1 or pre-treatment baseline (except alopecia).
  8. Karnofsky performance status (KPS) score ≥70%.
  9. Adequate organ function, including the following:

    1. Absolute neutrophil count (ANC) ≥ 1,000/μL, platelets ≥ 100,000/μL; Absolute lymphocyte count ≥ 500/uL; CD4/CD8 ratio ≥1 or ≥ 400/uL;
    2. Serum creatinine \< 1.5 × the upper limit of normal (ULN);
    3. Bilirubin \< 1.5 × ULN;
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 × ULN.
  10. Women of childbearing potential must have a negative urine pregnancy test within 21 days prior to the start of treatment.
  11. Female subjects of childbearing potential and sexually active male subjects must agree to use an acceptable form of contraception for heterosexual activity (i.e., oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy of their sexual partner(s) for > 40 days before Screening, during the study, and for 60 days after the last dose of study drug).
  12. Female subjects without childbearing potential (spontaneous amenorrhea for >12 months or surgically sterilized by tubal ligation, hysterectomy, or bilateral oophorectomy > 6 months before Screening) are eligible for inclusion without contraceptive use restriction.
  13. Able and willing to comply with protocol requirements, in the opinion of the Investigator.
  14. Written consent has been obtained.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Contrast-enhancing residual tumor that is any of the following:

    1. An area greater than 600 mm2;
    2. Multicentric (defined as two separate areas of contrast enhancement measuring at least 1 cm in 2 planes that are not contiguous on either fluid-attenuated inversion recovery (FLAIR) or T2 sequences);
    3. Associated with either diffuse sub-ependymal or dissemination.
  2. If recurrent GBM was previously a lower grade glioma and wildtype IDH1/2 status has not been confirmed.
  3. Requirement of systemic therapy > 2 mg/day of dexamethasone or equivalent during the 5 days prior to the start of treatment.
  4. Evidence of HCMV viremia in plasma of > 18,200 (4.3log10) IU/mL using FDA approved COBAS® AmpliPrep/COBAS® TaqMan® HCMV test (Roche) or other qualified HCMV assay.
  5. Prior treatment involving immunotherapy, including oncolytic viruses, therapeutic vaccination, or biologics presumed to have immunomodulatory effects. Prior bevacizumab therapy is allowed, requiring at least 28 days before randomization.
  6. Surgical resection or major surgical procedure within 14 days prior to the start of treatment, or stereotactic within 7 days prior to the start of treatment.
  7. Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following first recurrence/progressive disease. Excluded local therapies include stereotactic radiation boost, implantation of carmustine biodegradable wafers (Gliadel), intratumoral or convectionenhanced delivery administered agents, etc.
  8. More than 1 (one) (as an example, temozolomide given with radiotherapy and after radiotherapy before recurrence is considered a single line).
  9. Concurrent therapy with Optune® or use within 1 week of start of treatment. Previous use of Optune® in the primary setting does not preclude participation in this clinical trial.
  10. Active infection requiring intravenous antibiotics or antivirals.
  11. History of cancer (other than GBM or prostate) within the past 2 years that has or local recurrence potential and could negatively impact survival and/or potentially confound tumor response assessments within this study.
  12. Known disease or active systemic disease such as systemic lupus erythematosus, infection, virus or virus infections. Subjects with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  13. Any known allergies to the ingredients of VBI-1901 or GM-CSF or carmustine or lomustine.
  14. Evidence of intra- or peri-tumoral hemorrhage on baseline MRI scan, other than those that are ≤Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans.
  15. Any medical or social condition which in the investigator's opinion makes the subject unsuitable for study participation. For instance, lack of family or social support structure that would preclude continued participation in the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Part A Dose Level 1

    VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections

    Biological: VBI-1901

  • Experimental
    Part A Dose Level 2

    VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections

    Biological: VBI-1901

  • Experimental
    Part A Dose Level 3

    VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections

    Biological: VBI-1901

  • Experimental
    Part B GM-CSF Adjuvant

    VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 to 0.4 mL volume, given in two to four equal ID injections.

    Biological: VBI-1901

  • Experimental
    Part B AS01B Adjuvant

    VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection

    Biological: VBI-1901

  • Experimental
    Part C VBI-1901 with GM-CSF Adjuvant

    VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.

    Biological: VBI-1901

  • Active comparator
    Part C Standard of Care Treatment

    Single-agent standard-of-care (SOC) treatment with either carmustine intravenously at a dose of 150 mg/m² or lomustine orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg).

    Drug: Carmustine · Drug: Lomustine

Interventions

  • BiologicalVBI-1901

    The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.

  • Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.

    Also known as: BiCNU

  • Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.

    Also known as: Gleostine

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT) occurring during Part A of the study

    Time frame: Through 14 days after each study vaccination

  2. Occurrence of AEs during each treatment cycle

    Time frame: Through 28 days after each study vaccination

Secondary outcomes

  1. Serum antibody immune response

    Assessment of IgG antibody to HCMV gB antigen by ELISA

    Time frame: Baseline and 2 weeks after each dose of vaccine in Part A and Part B and every 3 months in Part C

  2. Cellular immune responses

    Assessment of IFN-γ and IL-5 positive peripheral blood mononuclear cells by ELISPOT

    Time frame: Baseline and 2 weeks after each dose of vaccine in Part A and Part B and every 3 months in Part C

  3. Progression free survival (PFS)

    Progression free survival (PFS) from date of first dose to date of progression (per iRANO/RANO criteria) or death, as well as at 6, 12, 18 and 24 months.

    Time frame: From the date of first dose to date of progression or death, as well as at 6, 12, 18 and 24 months

  4. Overall survival (OS)

    Time frame: 6, 12, 18 and 24 months from date of first dose

  5. Median overall survival in Part A and Part B of the study

    Time frame: Date of first dose to date of death from any cause, assessed up to 18 months

  6. Reduction in steroid use compared to baseline

    Time frame: Baseline to study completion, an average of 12 months

  7. Change in quality of life (QOL questionnaire) compared to baseline

    Time frame: Baseline to study completion, an average of 12 months

  8. Tumor response rates (TRR) in Part C of the study

    Complete response rate, partial response rate, progressive disease and stable disease

    Time frame: Baseline to study completion, an average of 12 months

  9. Safety and efficacy of VBI-1901 compared to standard of care (SOC) in Part C of study

    An integrated analysis of safety and efficacy (OS, TRR, PFS) in subjects receiving VBI-1901 at 10 µg dose formulated with GM-CSF as compared to subjects receiving SOC

    Time frame: Baseline to study completion, an average of 12 months

07

Study locations

12 sites
  • University of California, Irvine
    Irvine, California 92868, United States
  • University of California, San Diego
    La Jolla, California 92093, United States
  • University of California, Los Angeles Neuro-Oncology Program
    Los Angeles, California 90095, United States
  • Stanford
    Stanford, California 94305, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • The Valley Hospital - Neurosurgeons of New Jersey
    Ridgewood, New Jersey 07450, United States
  • The Neurological Institute of New York Columbia University Medical Center
    New York, New York 10032, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Providence - Swedish Medical Center
    Seattle, Washington 98122, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jul 2025, 91 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2017
First posted
Dec 26, 2017
StartActual
Dec 6, 2017
Primary completionActual
Jul 30, 2025
CompletionActual
Aug 30, 2025
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03382977
Lead sponsor
VBI Vaccines Inc.
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Dec 6, 2017
Primary completion
Jul 30, 2025
Completion
Aug 30, 2025
Last update
May 8, 2026

Study contacts

Francisco Diaz-Mitoma, MD
study director · Variation Biotechnologies Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion